Five Ways R.F.K. Jr. Could Undermine Lifesaving Childhood Vaccines

Published On Nov 19, 2024, 5:04 AM

Robert F. Kennedy Jr., known for his criticism of vaccines, is potentially set to become the U.S. Secretary of Health and Human Services (H.H.S.). If confirmed, he may impact immunization policies and vaccine research in the country. Despite assurances that he will not ban vaccines, his influence could lead to reduced vaccination rates and a delay in vaccine development. This raises concerns about public health, as past vaccination programs have significantly decreased disease cases and hospitalizations.

Stock Forecasts

Investors should be wary of companies that rely heavily on vaccine sales, as shifts in public health policy under Kennedy could lead to lower vaccination rates. This could negatively impact revenue for vaccine manufacturers and related biotech firms.

ETFs focused on healthcare and biotechnology might see volatility as public sentiment and vaccination rates could change with Kennedy's policies. However, diversified healthcare ETFs may remain stable.

Related News

Wall Street is absorbing a jump in retail sales and Jerome Powell's hawkish comments as Trump-fueled optimism starts to wear off.

SPY
PLTR
PFE
MRNA

Wall Street is absorbing a jump in retail sales and Jerome Powell's hawkish comments as Trump-fueled optimism starts to wear off.

SPY
MRNA

Investors are "spooked" by plan to name a vaccine-sceptic as US health secretary, analysts say.

PFE
MRNA
AZN
XLV